← Human Trials & Peer-Reviewed Studies
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
Plain-language guide to PMID 30924737 (2019): observational study of Octreotide and Somatostatin.
Key Facts
- PMID
- 30924737
- Journal
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Year
- 2019
- Study type
- Observational Study
- Authors
- Ryan P et al. (8 authors)
- DOI
- 10.1177/1078155219839458
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Octreotide and Somatostatin, published as an observational study.
The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients.
Why It Was Studied
Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
However, each agent possesses unique attributes in terms of their drug-delivery characteristics.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.
This study employed an observational time and motion design among patients treated with lanreotide or octreotide LAR across five US cancer centers.
Baseline patient data collection included age, disease grade and duration, prior therapies and performance status.
How the Study Was Run
Drug-delivery time (drug preparation and administration), total patient time and resource use data were collected for gastroenteropancreatic neuroendocrine tumors receiving lanreotide (n = 22) or octreotide LAR (n = 22).
Following each administration, qualitative data on the drug-delivery experience was collected from patients and nurses.
What Was Measured
Topics PubMed links to this paper include Antineoplastic Agents, Attitude of Health Personnel, Drug Compounding, Equipment Failure, Health Resources, Injections and Intestinal Neoplasms.
Author keywords: Lanreotide, cost, neuroendocrine tumors, octreotide and time and motion.
What This Means in Plain Language
This is an observational study of Octreotide and Somatostatin.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2019 (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.